122 related articles for article (PubMed ID: 11937746)
1. Atrophie blanche associated with interferon-alfa adjuvant therapy for melanoma: a cutaneous side effect related to the procoagulant activity of interferon?
Bugatti L; Filosa G; Nicolini M; Filosa A; Verdolini R
Dermatology; 2002; 204(2):154. PubMed ID: 11937746
[No Abstract] [Full Text] [Related]
2. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
Guillot B; Blazquez L; Bessis D; Dereure O; Guilhou JJ
Dermatology; 2004; 208(1):49-54. PubMed ID: 14730237
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary and cutaneous sarcoidosis associated with interferon therapy for melanoma.
Pelletier F; Manzoni P; Jacoulet P; Humbert P; Aubin F
Cutis; 2007 Nov; 80(5):441-5. PubMed ID: 18189032
[TBL] [Abstract][Full Text] [Related]
6. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
[No Abstract] [Full Text] [Related]
7. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
[TBL] [Abstract][Full Text] [Related]
8. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
Ockenfels M; Lisch W
Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
[TBL] [Abstract][Full Text] [Related]
9. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury A; El Sayed F; Farah C; Bazex J
J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
[No Abstract] [Full Text] [Related]
10. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
11. Building upon the standard of care in adjuvant therapy of high-risk melanoma.
Kirkwood JM
J Clin Oncol; 2005 Dec; 23(34):8559-63. PubMed ID: 16260699
[No Abstract] [Full Text] [Related]
12. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
Lane AM; Egan KM; Harmon D; Holbrook A; Munzenrider JE; Gragoudas ES
Ophthalmology; 2009 Nov; 116(11):2206-12. PubMed ID: 19744725
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant interferon alfa-2b for high-risk melanoma.
Retsas S
J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
[No Abstract] [Full Text] [Related]
15. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
Kiley KE; Gale DM
Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
[TBL] [Abstract][Full Text] [Related]
16. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
[No Abstract] [Full Text] [Related]
17. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
Fox M; Tahan S; Kim CC
Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
[TBL] [Abstract][Full Text] [Related]
18. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
Kimyai-Asadi A; Usman A
J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
[TBL] [Abstract][Full Text] [Related]
19. Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.
Garcia-Arumi J; Morral Palau M; Montolio Gil M; Blasco Garrido H; Sararols Ramsay L; Segura García A
Br J Ophthalmol; 2006 Apr; 90(4):516-8. PubMed ID: 16547342
[No Abstract] [Full Text] [Related]
20. [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].
Richtig E; Langmann G; Schlemmer G; Müllner K; Papaefthymiou G; Bergthaler P; Smolle J
Ophthalmologe; 2006 Jun; 103(6):506-11. PubMed ID: 16763868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]